Anti-Mouse CD70 – Biotin

BALB/c mouse B lymphoma A20.J2

This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

IP
B
FC
For specific conjugates of this clone, review literature for suggested application details.

FR70 activity is directed against mouse CD70.

CD70, a type II transmembrane glycoprotein of the TNF family with cytokine activity, is the ligand for the CD27 receptor¹. Mouse CD70 (mCD70) has a potent co-stimulatory effect on T cell proliferation¹ and acts as an immune-checkpoint². In mouse, but not in humans, the CD70-CD27 axis mediates a negative feedback system that enables the immune system to modulate hematopoiesis². Additionally, CD70-CD27 interactions are important to the formation of memory and plasma B cells. Immunotherapies that aim to eradicate tumor cells by targeting CD70 overexpression are being developed². FR70 inhibits mCD70 binding to mCD27-Ig, a recombinant soluble form of mCD27¹, as well as to mCD27 in vitro^3,4 and in vivo⁵. FR70 was produced by immunizing an F344/DuCrj rat with A20 cells and fusing the splenocytes with P3U1 cells to create hybridoma lines¹. HAT selection was performed, and FR70 was identified by its strong reactivity against mCD70-BHK21 cells. Blocking with FR70 can prolong graft acceptance^6,7. When mouse cardiac allogenic graft recipients are treated with FR70, tolerogenic dendritic cells and T regulatory cells are induced, resulting in decreased cytotoxic T lymphocyte proliferation as well as long-term graft acceptance⁶. Blocking with FR70 also prolongs mouse corneal graft survival⁷.

Mouse CD70 is transiently expressed on the surfaces of antigen-activated B and T cells, natural killer cells, and mature dendritic cells. CD70 is also aberrantly expressed on malignant cancer cells

CD27

1. Oshima H, Nakano H, Nohara C, et al. Int Immunol. 10(4):517-526. 1998.
2. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. J Exp Clin Cancer Res. 41(1):12. 2022.
3. Mahmud SA, Manlove LS, Schmitz HM, et al. Nat Immunol. 15(5):473-481. 2014.
4. Kuka M, Munitic I, Giardino Torchia ML, et al. J Immunol. 191(5):2282-2289. 2013.
5. Ballesteros-Tato A, León B, Lee BO, et al. Immunity. 41(1):127-140. 2014.
6. Zhao J, Que W, Du X, et al. Front Immunol. 11:555996. 2021.
7. Narimatsu A, Hattori T, Usui Y, et al. Exp Eye Res. 199:108190. 2020.
8. Wensveen FM, Unger PP, Kragten NA, et al. J Immunol. 188(9):4256-4267. 2012.
9. Tewalt EF, Cohen JN, Rouhani SJ, et al. Blood. 120(24):4772-4782. 2012.
10. Ho PC, Meeth KM, Tsui YC, et al. Cancer Res. 74(12):3205-3217. 2014.